Fragment-based drug discovery specialist Zenobia will provide its technology platform and expertise to researchers at the Alzheimer’s Drug Discovery Foundation (ADDF). The firm will also provide ADDF with its Fragment Library 1 at a reduced price, along with access to its medicial chemistry capabilities for optimizing fragments to leads with the desired CNS ADME/pharmacokinetic properties.

Zenobia is exploiting its platform of fragment-based lead discovery, structural biology, and crystallography technologies to identify drug-like compounds that will cross the blood-brain barrier. Core technologies include a gene-to-structure platform with in-house cloning, expression and purification in bacterial, insect, and mammalian cells, two custom fragment libraries, fragment screening by multiple methods, and assay development. 

The firm is leveraging these technologies both through the development of an in-house CNS drug pipeline targeting Parkinson’s, Alzheimer’s, and Huntington’s diseases, and through collaborations, partnerships, and technology-based agreements. 

Previous articleQuintiles Snaps Up EA
Next articleHorizon Strikes X-Man Deal with ATCC